Status:
COMPLETED
The Impact of Renalof® Dietary Supplement on Upper Urinary Tract Stone Volume
Lead Sponsor:
Aristotle University Of Thessaloniki
Conditions:
Calculus of Upper Urinary Tract (Disorder)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Following informed consent, all recruited patients will have a baseline non-contrast CT scan performed at the radiology department of "G. Gennimatas" hospital and reported by the same dedicated urorad...
Detailed Description
A total of 82 patients with renal stone or ureteral stones measured on a CT scan performed no later than 1 month prior to randomization, will be recruited in the study. Full medical history as well as...
Eligibility Criteria
Inclusion
- Age over 18 years
- Upper urinary tract stones
- Stone density \> 500 HU on CT (Mean Hounsfield Units of the largest stone)
- Ability to understand and provide a written informed consent to participate in the study
Exclusion
- Staghorn stones occupying renal calyces and pelvis
- Stone composition other than calcium, indirectly assessed or determined using the Hounsfield stone density units (a Mean Hounsfield score of \< 500 units will be considered)
- Use of other urinary urinary stone treatments
- Use of magnesium supplementation
- Chronic kidney disease (CKD) with eGFR\<30 ml/sec
- Pregnancy
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT04860492
Start Date
September 1 2020
End Date
December 1 2022
Last Update
September 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
G. Gennimatas Hospital
Thessaloniki, Greece, 54621